H.C. Wainwright analyst Yi Chen reiterated a Buy rating on Co-Diagnostics (CODX – Research Report) today and set a price target of $15.00. The company’s shares closed last Wednesday at $9.61.
According to TipRanks.com, Chen is a 5-star analyst with an average return of 25.6% and a 39.8% success rate. Chen covers the Healthcare sector, focusing on stocks such as Ortho Clinical Diagnostics Holdings, Interpace Diagnostics Group, and HTG Molecular Diagnostics.
Co-Diagnostics has an analyst consensus of Moderate Buy, with a price target consensus of $15.00.
See the top stocks recommended by analysts >>
The company has a one-year high of $20.69 and a one-year low of $7.01. Currently, Co-Diagnostics has an average volume of 490.8K.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Co-Diagnostics, Inc. is a molecular diagnostics company, which engages in the development, manufacture, and marketing of diagnostics technology. The company’s products are utilized for tests that are designed using the detection and analysis of nucleic acid molecules. It also uses its proprietary technology to design tests to locate genetic markers for use in industries other than infectious disease and license the use of those tests to specific customers. The company was founded by Brent C. Satterfield and Dwight Howard Egan on April 18, 2013 and is headquartered in Salt Lake City, UT.
Read More on CODX:
- Analysts Offer Insights on Healthcare Companies: HTG Molecular Diagnostics (HTGM), Sol-Gel Technologies (SLGL) and Ikena Oncology (IKNA)
- How to Make Smart Investment Decisions in 2022
- H.C. Wainwright Thinks Elevation Oncology’s Stock is Going to Recover
- H.C. Wainwright Thinks Osmotica Pharmaceuticals’ Stock is Going to Recover
- Analysts Are Bullish on These Healthcare Stocks: Durect (DRRX), Outlook Therapeutics (OTLK)
